Neurokine Pharmaceuticals Inc.- Consolidated Statement of Stockholders' Equity (USD $)	Common Stock	Common Stock Issuable	Share Subscription Received	Additional Paid-in Capital	Deficit Accumilated During the Development Stage	Total
Balance, Value at Jun. 09, 2002
Issuance of common stock for cash, Value	$ 45,000					$ 45,000
Issuance of common stock for cash, Shares	18,000,000
Issuance of common stock for services rendered, Value	60,000					60,000
Issuance of common stock for services rendered, Shares	400,000
Proceeds from share subscriptions received, Value			183,588			183,588
Net Loss					(122,578)	(122,578)
Balance, Value at Jan. 31, 2008	105,000		183,588		(122,578)	166,010
Balance, Shares at Jan. 31, 2008	18,400,000
Issuance of common stock for cash, Value	201,063		(183,588)			17,475
Issuance of common stock for cash, Shares	1,340,418
Net Loss					(653,761)	(653,761)
Issuance of common stock for license agreement, Value	500,000					500,000
Issuance of common stock for license agreement, Shares	4,000,000
Balance, Value at Jan. 31, 2009	806,063				(776,339)	29,724
Balance, Shares at Jan. 31, 2009	23,740,418
Issuance of common stock for cash, Value	20,421					20,421
Issuance of common stock for cash, Shares	89,200
Net Loss					(120,134)	(120,134)
Shares issuable for management fees, Value		32,000				32,000
Fair value of stock options granted, Value				42,159		42,159
Balance, Value at Jan. 31, 2010	826,484	32,000		42,159	(896,473)	4,170
Balance, Shares at Jan. 31, 2010	23,829,618
Issuance of common stock for cash, Value	30,849					30,849
Issuance of common stock for cash, Shares	6,000,000
Net Loss					(3,023,058)	(3,023,058)
Fair value of stock options granted, Value				5,076		5,076
Shares issued to settle debt, Value	10,000					10,000
Shares issued to settle debt, Shares	2,000,000
Shares issued for exercise of stock options, Value	2,540					2,540
Shares issued for exercise of stock options, Shares	400,000
Fair value of share purchase warrants exercised, Value				5,175		5,175
Shares issued for exercise of share purchase warrants, Value	7,620					7,620
Shares issued for exercise of share purchase warrants, Shares	1,200,000
Shares issued for management fees, Value	38,400	(32,000)				6,400
Shares issued for management fees, Shares	192,000
Balance, Value at Jan. 31, 2011	915,893			52,410	(3,919,531)	(2,951,228)
Balance, Shares at Jan. 31, 2011	33,621,618
Net Loss					1,417,734	1,417,734
Fair value of stock options granted, Value				5,785		5,785
Shares issued for conversion of debenture, Value	43,736					43,736
Shares issued for conversion of debenture, Shares	545,455					43,736
Shares issued for services, Value	126,519					126,519
Shares issued for services, Shares	1,600,000
Shares issuable for restructuring of debenture, Value		225,000				225,000
Fair value of share purchase warrants issued, Value				8,891		8,891
Beneficial conversion feature of convertible debenture, Value				100,000		100,000
Balance, Value at Jan. 31, 2012	1,086,148	225,000		167,086	(2,501,797)	(1,023,563)
Balance, Shares at Jan. 31, 2012	35,767,073
Net Loss					341,425	341,425
Contributed capital				7,500		7,500
Balance, Value at Jan. 31, 2013	$ 1,086,148	$ 225,000		$ 174,586	$ (2,160,372)	$ (674,638)
Balance, Shares at Jan. 31, 2013	35,767,073